EXTON, Pa.--(BUSINESS WIRE)--Melior Discovery, Inc. announced today that it has signed an agreement with AstraZeneca PLC under which Melior’s in-vivo theraTRACE® indications discovery platform will be used to evaluate the therapeutic activity of selected AstraZeneca compounds.
“Our agreement represents a significant opportunity for Melior to deliver value to AstraZeneca through the application of our unique and innovative in vivo testing platform,” said Andrew Reaume, PhD, President and CEO of Melior. ”We look forward to a productive collaboration.”
Melior Discovery Overview
Melior Discovery is leading the transformation of drug repositioning with its unique theraTRACE platform of multiplexed in vivo models. Melior is using theraTRACE to both build an internal pipeline of development candidates as well as sharing this capability with pharmaceutical and biotechnology company partners. In the former case, Melior identifies and develops “privileged” compounds that have been discontinued by other companies for lack of efficacy in their original indications. Melior is also able to identify appropriate compounds for repositioning by leveraging a close working relationship with the renowned medicinal chemist, Dr. Christopher Lipinski. In its partnered arrangements, Melior offers pharmaceutical partners an approach to expand their late-stage pipelines with safe, high-quality drug candidates
Melior Discovery is located in Exton, PA.